What makes an “observation” an “insight” in the world of Medical Affairs? This is the question tackled by MedicalAffairs professionals on this month’s Elevate podcast from the Medical Affairs Professionals Society (MAPS).
What makes an “observation” an “insight” in the world of Medical Affairs? This is the question tackled by Medical Affairs professionals on this month’s Elevate podcast from the Medical Affairs Professionals Society (MAPS).
LARVOL VP of Marketing Abby Fraser joined industry experts Carol Collins-Carriveau, Senior Director of Medical Sciences at Gilead Sciences, and Jennifer Schneider, Director of Field Medical Alignment at Novo Nordisk, to unpack this important topic.
Collectively, the group talked about how to tell the difference between insights and observations in Medical Affairs, and how those insights are collected and used in the industry. The insights collected by Medical Affairs teams factor not only into medical strategy but also strategy across entire companies, shaping clinical development as well as commercial strategy.
Click below to listen to the full 20-minute conversation which covers:
LARVOL is pleased to sponsor this conversation through MAPS and to work with the Medical Affairs teams at Gilead and Novo Nordisk to achieve their strategic goals. Learn more about our digital tools to support insight generation by requesting a demo of OMNI, our KOL monitoring digest and online platform.
The advent of precision oncology is marked by many new changes and improvements in diagnostic, prognostic and treatment methods for cancer patients. Researchers looking to bring new drugs to market are now also privy to a vast database of material from previously conducted studies thanks to a push forward in research collaborations and the creation of shared data hubs.